본문으로 건너뛰기
← 뒤로

Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?

1/5 보강
Biomedicines 📖 저널 OA 100% 2021: 1/1 OA 2022: 22/22 OA 2023: 20/20 OA 2024: 55/55 OA 2025: 152/152 OA 2026: 94/94 OA 2021~2026 2025 Vol.13(4)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: NOD for pancreatic cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Nonetheless, the number of publications is limited, and the downfalls of using AI are not well highlighted. This narrative review presents a summary of previous publications, recent advancements and feasible solutions for effective screening of patients with NOD for pancreatic cancer.

Mejza M, Bajer A, Wanibuchi S, Małecka-Wojciesko E

📝 환자 설명용 한 줄

Pancreatic cancer is one of the most lethal neoplasms.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Mejza M, Bajer A, et al. (2025). Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?. Biomedicines, 13(4). https://doi.org/10.3390/biomedicines13040836
MLA Mejza M, et al.. "Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?." Biomedicines, vol. 13, no. 4, 2025.
PMID 40299428 ↗

Abstract

Pancreatic cancer is one of the most lethal neoplasms. Despite considerable research conducted in recent decades, not much has been achieved to improve its survival rate. That may stem from the lack of effective screening strategies in increased pancreatic cancer risk groups. One population that may be appropriate for screening is new-onset diabetes (NOD) patients. Such a conclusion stems from the fact that pancreatic cancer can cause diabetes several months before diagnosis. The most widely used screening tool for this population, the ENDPAC (Enriching New-Onset Diabetes for Pancreatic Cancer) model, has not achieved satisfactory results in validation trials. This provoked the first attempts at using artificial intelligence (AI) to create larger, multi-parameter models that could better identify the at-risk population, which would be suitable for screening. The results shown by the authors of these trials seem promising. Nonetheless, the number of publications is limited, and the downfalls of using AI are not well highlighted. This narrative review presents a summary of previous publications, recent advancements and feasible solutions for effective screening of patients with NOD for pancreatic cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기